Table 1 Summary of clinico-pathological variables in breast cancer patients (n = 791).
From: PALB2 germline mutations in a large cohort of Middle Eastern breast-ovarian cancer patients
Clinico-pathological variable | n (%) |
|---|---|
Age at diagnosis, years | |
Mean ± SD | 40.9 ± 9.8 |
Median (range) | 39 (13–84) |
≤ 30 | 77 (9.8) |
31–40 | 387 (48.9) |
41–50 | 220 (27.8) |
51–60 | 68 (8.6) |
> 60 | 39 (4.9) |
Family history of cancer | |
No | 529 (66.9) |
Yes | 262 (33.1) |
Bilateral breast cancer | |
Yes | 15 (1.9) |
No | 776 (98.1) |
Histologic grade | |
Well differentiated | 50 (6.3) |
Moderately differentiated | 342 (43.2) |
Poorly differentiated | 360 (45.5) |
Unknown | 40 (5.0) |
Tumor size | |
T1 | 208 (26.3) |
T2 | 329 (41.6) |
T3 | 131 (16.6) |
T4 | 101 (12.8) |
Unknown | 22 (2.7) |
Lymph node status | |
Negative | 294 (37.2) |
Positive | 475 (60.1) |
Unknown | 22 (2.7) |
Distant metastasis | |
Absent | 697 (88.1) |
Present | 72 (9.2) |
Unknown | 22 (2.7) |
Stage | |
I | 111 (14.0) |
II | 317 (40.1) |
III | 269 (34.0) |
IV | 72 (9.2) |
Unknown | 22 (2.7) |
ER | |
Positive | 439 (55.5) |
Negative | 352 (44.5) |
PR | |
Positive | 401 (50.7) |
Negative | 390 (49.3) |
Her-2 neu | |
Positive | 254 (32.1) |
Negative | 537 (67.9) |
Triple negative breast cancer | |
Yes | 199 (25.2) |
No | 592 (74.8) |
